Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Future patients might benefit from a combination of linezolid (LIN) and clarithromycin (CLA)
in the treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis
(MDR/XDR-TB) due to possible synergistic activity as shown in in vitro experiments in
different Mycobacteria strains. The investigators observed increased LIN serum levels in
three cases after combining LIN and CLA of which the investigators described one in a case
report (Bolhuis et al). The investigators suggest to conduct a prospective pharmacokinetic
study in MDR- and XDR-TB patients to quantify the above described interaction between LIN and
CLA.